File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Soluble E-cadherin is a valid prognostic marker in gastric carcinoma

TitleSoluble E-cadherin is a valid prognostic marker in gastric carcinoma
Authors
KeywordsE-cadherin
Gastric cancer
Tumour marker
Issue Date2001
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
Citation
Gut, 2001, v. 48 n. 6, p. 808-811 How to Cite?
AbstractBackground - Gastric cancer remains a major cause of cancer mortality globally but no good prognostic tumour marker is available. Soluble fragment of E-cadherin protein has been reported to increase in the sera of patients with cancer and recently was found to be elevated in 67% of patients with gastric cancer. Aims - To investigate if serum soluble E-cadherin is a valid prognostic marker in gastric cancer. Methods - Concentrations of soluble E-cadherin from 116 patients with histologically confirmed gastric adenocarinoma and 40 healthy subjects were measured using an immunoenzymometric method with a commercially available sandwich ELISA kit based on monoclonal antibodies. Results - The logarithm of the means of soluble E-cadherin concentration was significantly higher in patients with gastric cancers (mean 3.85 (SD 0.28)) than in healthy subjects (3.71 (0.18)) (p=0.001), and in palliative/conservatively treated cancers (3.91 (0.35)) than in operable cancers (3.78 (0.19)) (p=0.015). The logarithm of the concentrations correlated with tumour size (p=0.032) and carcinoembryonic antigen concentrations (p=0.001). The cut off value calculated from discriminant analysis on operability and inoperability/palliative treatment was 7025 ng/ml. Soluble E-cadherin concentrations higher than this cut off value predicted tumour (T4) depth invasion (p=0.020, confidence interval (CI) 1.008-1.668) and palliative/conservative treatment (p=0.023, CI 1.038-2.514). In contrast, the relative risks for lymph node (N2) metastasis, distant metastasis, and stage III/IV disease were 1.41, 1.33, and 1.55 respectively, despite not reaching statistical significance. Conclusion - Serum soluble E-cadherin is a potential valid prognostic marker for gastric cancer. A high concentration predicts palliative/conservative treatment and T4 invasion.
Persistent Identifierhttp://hdl.handle.net/10722/43096
ISSN
2023 Impact Factor: 23.0
2023 SCImago Journal Rankings: 8.052
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorChu, KMen_HK
dc.contributor.authorLam, CMen_HK
dc.contributor.authorKwok, Een_HK
dc.contributor.authorLeung, SYen_HK
dc.contributor.authorYuen, STen_HK
dc.contributor.authorLaw, SYKen_HK
dc.contributor.authorHui, WMen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorWong, CYen_HK
dc.contributor.authorHu, HCen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2007-03-23T04:38:46Z-
dc.date.available2007-03-23T04:38:46Z-
dc.date.issued2001en_HK
dc.identifier.citationGut, 2001, v. 48 n. 6, p. 808-811en_HK
dc.identifier.issn0017-5749en_HK
dc.identifier.urihttp://hdl.handle.net/10722/43096-
dc.description.abstractBackground - Gastric cancer remains a major cause of cancer mortality globally but no good prognostic tumour marker is available. Soluble fragment of E-cadherin protein has been reported to increase in the sera of patients with cancer and recently was found to be elevated in 67% of patients with gastric cancer. Aims - To investigate if serum soluble E-cadherin is a valid prognostic marker in gastric cancer. Methods - Concentrations of soluble E-cadherin from 116 patients with histologically confirmed gastric adenocarinoma and 40 healthy subjects were measured using an immunoenzymometric method with a commercially available sandwich ELISA kit based on monoclonal antibodies. Results - The logarithm of the means of soluble E-cadherin concentration was significantly higher in patients with gastric cancers (mean 3.85 (SD 0.28)) than in healthy subjects (3.71 (0.18)) (p=0.001), and in palliative/conservatively treated cancers (3.91 (0.35)) than in operable cancers (3.78 (0.19)) (p=0.015). The logarithm of the concentrations correlated with tumour size (p=0.032) and carcinoembryonic antigen concentrations (p=0.001). The cut off value calculated from discriminant analysis on operability and inoperability/palliative treatment was 7025 ng/ml. Soluble E-cadherin concentrations higher than this cut off value predicted tumour (T4) depth invasion (p=0.020, confidence interval (CI) 1.008-1.668) and palliative/conservative treatment (p=0.023, CI 1.038-2.514). In contrast, the relative risks for lymph node (N2) metastasis, distant metastasis, and stage III/IV disease were 1.41, 1.33, and 1.55 respectively, despite not reaching statistical significance. Conclusion - Serum soluble E-cadherin is a potential valid prognostic marker for gastric cancer. A high concentration predicts palliative/conservative treatment and T4 invasion.en_HK
dc.format.extent184559 bytes-
dc.format.extent27648 bytes-
dc.format.extent454989 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/msword-
dc.format.mimetypeapplication/pdf-
dc.languageengen_HK
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/en_HK
dc.relation.ispartofGuten_HK
dc.rightsGut. Copyright © B M J Publishing Group.en_HK
dc.subjectE-cadherinen_HK
dc.subjectGastric canceren_HK
dc.subjectTumour markeren_HK
dc.subject.meshAdenocarcinoma - blood - diagnosisen_HK
dc.subject.meshCadherins - blooden_HK
dc.subject.meshStomach neoplasms - blood - diagnosisen_HK
dc.subject.meshTumor markers, biological - blooden_HK
dc.subject.meshPredictive value of testsen_HK
dc.titleSoluble E-cadherin is a valid prognostic marker in gastric carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0017-5749&volume=48&issue=6&spage=808&epage=811&date=2001&atitle=Soluble+E-cadherin+is+a+valid+prognostic+marker+in+gastric+carcinomaen_HK
dc.identifier.emailChu, KM: chukm@hkucc.hku.hken_HK
dc.identifier.emailLeung, SY: suetyi@hku.hken_HK
dc.identifier.emailLaw, SYK: slaw@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityChu, KM=rp00435en_HK
dc.identifier.authorityLeung, SY=rp00359en_HK
dc.identifier.authorityLaw, SYK=rp00437en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1136/gut.48.6.808en_HK
dc.identifier.pmid11358900-
dc.identifier.pmcidPMC1728335-
dc.identifier.scopuseid_2-s2.0-0035018890en_HK
dc.identifier.hkuros63826-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035018890&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume48en_HK
dc.identifier.issue6en_HK
dc.identifier.spage808en_HK
dc.identifier.epage811en_HK
dc.identifier.isiWOS:000168900100017-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChan, AOO=7403167965en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK
dc.identifier.scopusauthoridChu, KM=7402453538en_HK
dc.identifier.scopusauthoridLam, CM=36799183200en_HK
dc.identifier.scopusauthoridKwok, E=7005571440en_HK
dc.identifier.scopusauthoridLeung, SY=7202044886en_HK
dc.identifier.scopusauthoridYuen, ST=7103160927en_HK
dc.identifier.scopusauthoridLaw, SYK=7202241293en_HK
dc.identifier.scopusauthoridHui, WM=7103196477en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridWong, CY=14824318400en_HK
dc.identifier.scopusauthoridHu, HC=7404097674en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK
dc.identifier.issnl0017-5749-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats